Biopolym. Cell. 2015; 31(6):465-472.
http://dx.doi.org/10.7124/bc.000905
Viruses and Cell
Study of antiviral activity of a new plant origin preparation neoflazidum on a model of the hepatitis C virus
1Porva Yu. I., 1Rybalko S. L., 2Palchykovs’ka L. I., 1Atamanyuk V. P.
  1. Gromashevsky L. V. Institute of Epidemiology and Infection Diseases, NAMS of Ukraine
    5, Amosova Str., Kyiv, Ukraine, 03038
  2. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680

Abstract

Aim. Investigation of antiviral activity of a new plant origin preparation – neoflazidum, a form of proteflazidum Methods. A model of hepatitis C virus-producing Jurkat cell culture (JurkatHCV) which has been previously transfected with complementary DNA preparations isolated from different types of hepatitis C virus (HCV). Results.To obtain these preparations, HCV RNA preparations were isolated from viral material of HCV-diseased patients, the transfecting agent Turbofect being used. The cytotoxic dose (CD50) was shown to be 37.2 μg/ml, the effective dose (ED50) being 0.46 μg/ml for the HCV type 3a; this dose, however, was as high as 3.7 μg/ml when neoflazidum had been tested for HCV type 1b. Therefore, the selectivity index for the HCV type 3a reached 80.8 in the JurkatHCV-3a cell system, being as low as 10.0 for the HCV type 1b. Conclusion. Using a model system RNAP T7, the antiviral neoflazidum activity was demonstrated to be realized due to interferons α- and γ-induction and RNA synthesis inhibition.
Keywords: antiviral activity, neoflazidum, hepatitis C virus, transfecting, interferons α- and γ-induction, model system RNAP T7
Full text: (PDF, in English)

References

[1] Porva YI, Rybalko SL, Kuklin FV et al. HCV-producing cell cultures obtained by transfection techniques. Symposium “HCV animal models and vaccine development” 16-17.05.2013, Tallinn, Estonia:44.
[2] L'vov DK. [Viral hepatitis]. Vopr Virusol. 2002;47(6):44-6.
[3] van der Meer AJ, Wedemeyer H, Feld JJ, Dufour JF, Zeuzem S, Hansen BE, Janssen HL. Life expectancy in patients with chronic HCV infection and cirrhosis compared with a general population. JAMA. 2014;312(18):1927-8.
[4] Gural AL, Marievskiy VF, Sergeyeva TA, Shaginyan VR, Ruban OM. Characteristics and trends of hepatitis’ C epidemic process in Ukraine. Profilaktychna Meditsina. 2011;1 (13):9-18.
[5] Kamili S, Drobeniuc J, Araujo AC, Hayden TM. Laboratory diagnostics for hepatitis C virus infection. Clin Infect Dis. 2012;55 Suppl 1:S43-8.
[6] Chumak AA, Bieliayeva N.V. et al. Viral hepatitis C: Problems of carrier state, therapy, and prevention. Zh Akad Med Nauk Ukr. 2000; 6(1):65-81.
[7] Kwong AD, McNair L, Jacobson I, George S. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. Curr Opin Pharmacol. 2008;8(5):522-31.
[8] Perni RB, Almquist SJ, Byrn RA, Chandorkar G, Chaturvedi PR, Courtney LF, Decker CJ, Dinehart K, Gates CA, Harbeson SL, Heiser A, Kalkeri G, Kolaczkowski E, Lin K, Luong YP, Rao BG, Taylor WP, Thomson JA, Tung RD, Wei Y, Kwong AD, Lin C. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother. 2006;50(3):899-909.
[9] Maltais F, Jung YC, Chen M, Tanoury J, Perni RB, Mani N, Laitinen L, Huang H, Liao S, Gao H, Tsao H, Block E, Ma C, Shawgo RS, Town C, Brummel CL, Howe D, Pazhanisamy S, Raybuck S, Namchuk M, Bennani YL. In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats. J Med Chem. 2009;52(24):7993-8001.
[10] Abonyi DO, Adikwu MU, Esimone CO, Ibezim EC. Plants as sources of antiviral agents. Afr J Biotechnol. 2009;8(17):3989-94.
[11] Al Ashaal HA, Farghaly AA, Abd El Aziz MM, Ali MA. Phytochemical investigation and medicinal evaluation of fixed oil of Balanites aegyptiaca fruits (Balantiaceae). J Ethnopharmacol. 2010;127(2):495-501.
[12] Kaul TN, Middleton E Jr, Ogra PL. Antiviral effect of flavonoids on human viruses. J Med Virol. 1985;15(1):71-9.
[13] Pat N 2252221. Bomberdelli E, Valenti P. Derivatives of flavones, xanthones, and coumarins and a pharmaceutical composition including them. Russian Federation Patent for the Invention 20.05.2005.
[14] Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DI, Eley T, Guo T, Grasela DM, Pasquinelli C. Preliminary study of two antiviral agents for hepatitis C genotype 1. N Engl J Med. 2012;366(3):216-24.
[15] Deriabin PG, L'vov DK. [A highly productive variant of the hepatitis C virus. Isolation, identification, characteristics]. Dokl Akad Nauk. 1998;358(5):685-7.
[16] Attestation of Splitting Cell Lines – Substrates for Production and Control of Biological and Immunobiological Preparations. Methodical Recommendations. Moscow, 1989. 235 p.
[17] Patent of a useful model N 40311. Rybalko SL, Porva YuI, Dyadiun ST. et al. Mode of hepatitis C viruses cultivation. 25.03.2009.
[18] Avtsyn AP. A new neurogenous cell line RHNN-1 and its use in biotechnology. In the: Cultivation of Human and Animal Cells: Theses of the II All-Union Conference. Pushchino, 1985:75-6.
[19] Avtsyn AP, Kondakova LI, Khalanskiĭ AS, Poliakova GP, Chudinovskaia NV. [A new cell line of rat gasserian ganglion neurinoma NGUK-1]. Tsitologiia. 1989;31(1):97-102.
[20] Shcherbinska AM, Dyachenko NS, Rybalko SL at al. Study of antiviral effect of potential medicinal drugs. In the: Preclinical Study of Drugs. Methodical Guidelines. Kyiv. 2001;371-95.